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Abstract We have examined whether the apoptosis-speci¢c
protein p45ASP and human Apg5 are identical proteins. Like
p45ASP, myc-hApg5 cross-reacted with a c-Jun antibody and
V50% of myc-hApg5 was bound to a Triton X-100-insoluble
fraction in HeLa cells. However, soluble myc-hApg5 was de-
graded during apoptosis induced by staurosporine or TNFK/cy-
cloheximide whilst expression of soluble p45ASP was stabilised.
Furthermore, myc-hApg5 degradation was blocked by the cas-
pase inhibitor Boc-Asp(OMe)FMK whilst p45ASP expression
was eliminated. Moreover, myc-hApg5 (V32 kDa) never as-
sumed the size of p45ASP (45 kDa). It is therefore likely that
p45ASP and human Apg5 are distinct proteins although they do
share some common characteristics.
8 2002 Federation of European Biochemical Societies. Pub-
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1. Introduction
During an analysis of apoptosis, a series of proteins were
detected by Grand and colleagues on Western blots using an
anti-c-Jun antibody raised against the peptide sequence
TPTPTQFLCPKNVTD [1]. The most prominent band was
a protein of around 45 kDa. To identify this protein ^ termed
apoptosis-speci¢c protein, or ASP ^ Hammond et al. [2]
screened a human foetal liver cDNA expression library and
pulled out the 3P end of ASP cDNA. Sequence analysis of the
predicted protein encoded by the full length cDNA demon-
strated 26% identity with a yeast gene encoding apg5, which is
part of a novel conjugating system associated with autophagy
in yeast [3]. When Hammond et al. [2] transfected Cos-1 cells
with ASP cDNA for 48 h and Western blots were probed
using the c-Jun antibody, they found two bands of around
Mr 30 and 45 kDa, the latter being similar to the size of
p45ASP derived from apoptotic rodent cells. Since apg5 is
predicted to encode a protein of 32.4 kDa, and ASP cDNA
was noted to be expressed at this size in bacteria (Hammond
et al. [2], data was not shown), it was suggested that the 30
kDa band observed in the transfected cells is ‘native’ hApg5,
while the 45 kDa band is a post-translationally modi¢ed form
of hApg5. No band of 32.4 kDa, the size expected of native
hApg5, was detected before or during apoptosis. Hammond
and colleagues further noted that over-expression of hApg5 in
Cos-1 cells did not alter cellular morphology and did not
induce apoptosis.
The paper proposes that p45ASP (namely the protein of 45
kDa that is induced by apoptotic signals downstream of cas-
pases and which is recognised by the c-Jun antibody) is the
mammalian homologue of yeast Apg5. Many reviews in the
literature cite this work as providing evidence that apoptosis
and autophagy are linked by some common biochemical pro-
cesses (see for example [4^7]). This idea has been strengthened
by our ¢nding that apoptotic inducers can also promote au-
tophagy [8]. However, doubt as to the co-identity of the two
proteins has been cast by work from Esquerda and colleagues
[9,10], who showed that the reason c-Jun antibody recognises
many of the polypeptide ‘ASPs’ during apoptosis is because
they display neo-epitopes generated as a result of caspase-3
cleavage. Nevertheless, no direct evidence has been presented
refuting the idea that p45ASP is identical to hApg5 nor is it
clear whether hApg5 cross-reactivity with the c-Jun antibody
is generated as a result of caspase cleavage. We have at-
tempted to investigate these questions using myc-tagged
hApg5. Our data suggest that p45ASP and hApg5 are not
the same proteins, although they do share some common
characteristics.
2. Materials and methods
Human apg5 cDNA was subcloned from pSU18-apg5 (plasmid
kindly provided by Roger Grand and Ester Hammond, Birmingham
University) into the pRK5-myc vector (kindly provided by Alan Hall,
MRC-LCMB, UCL) and 1 Wg plasmid was transfected per 35 mm2
dish of 70% con£uent HeLa cells using 3 Wl Fugene 6 (Roche) follow-
ing the manufacturer’s instructions. HeLa cells were grown in Dul-
becco’s modi¢ed Eagle’s medium and 10% foetal bovine serum.
For immunocytochemistry, cells were ¢xed with 3% paraformalde-
hyde for 30 min at room temperature, permeabilised with 0.1% sap-
onin in phosphate-bu¡ered saline containing 1% bovine serum albu-
min for 20 min, and incubated for 1 h with a mouse monoclonal anti-
myc antibody (9E10, BabCo) and a rabbit polyclonal anti-c-Jun(N)
antibody (Santa Cruz, SC-45). This c-Jun antibody was raised against
the peptide sequence TPTPTQFLCPKNVTD and recognises the same
set of proteins as the Oncogene antibody used by Grand et al. [1] and
Hammond et al. [2] (H.W. Yung, data not shown). The anti-myc and
anti-c-Jun antibodies were visualised with goat anti-mouse FITC and
goat anti-rabbit cy3 conjugated antibodies (Jackson ImmunoRe-
search). Nuclei were visualised using Hoechst 33342 (Sigma). Cells
were imaged using a £uorescent microscope, and images were cap-
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tured using a Photometrics CCD camera. Images shown were col-
lected at the same exposure time.
For studies of protein expression during apoptosis, HeLa cells were
transfected for 48 h before treatment with 2.5 WM staurosporine (Sts)
(Sigma) or 50 ng/ml TNFK (Peprotech) and 20 Wg/ml cycloheximide
(CHX) (Sigma). Boc-Asp(O-Me)FMK (BAF) (Enzyme Systems Prod-
ucts) was used to inhibit caspase activity. Cells were lysed at the
appropriate time in a gentle lysis bu¡er containing 1% Triton X-100
[7], spun at 103 rpm for 10 min at 4‡C and the supernatant (sup) was
separated from the pellet, which was lysed in 2% sodium dodecyl
sulfate (SDS) lysis bu¡er [1]. The entire pellet of the relevant sup
was loaded per each sample. Protein samples were resolved on a
10% denaturing polyacrylamide gel and analysed by Western blotting
using the same antibodies used for immunocytochemistry. Amido
black was used to report protein loading.
For studies of hApg5 susceptibility to undergo cleavage by cas-
pases, full length hApg5 cDNA was subcloned into the pIRES vector
(a kind gift from Dr Anne Kaminski, Cambridge) and protein was
expressed using the TNT-coupled transcription/translation rabbit re-
ticulocyte lysate system (Promega) using the T7 promoter and trans-
lation grade [35S]methionine (Amersham Biotech). The cDNA of the
Rb(378^938) fragment cloned into the pING vector was obtained
from Dr Tony Kouzarides (Cambridge) and was similarly expressed
using the SP6 promoter and the TNT system. Translated products
were mixed in a caspase-3 assay bu¡er containing 50 mM HEPES
pH 7.4, 100 mM NaCl, 0.1% 3[3-cholaminopropyl diethylammonio]-
1-propane sulphonate (CHAPS), 1 mM EDTA, 10% glycerol, 10 mM
dithiothreitol (DTT) and 0.3 U/Wl recombinant caspase-3 (BIOMOL).
Following a 16 h incubation at 30‡C, the reaction mixture was
resolved using SDS^PAGE and the dried gel was exposed to a phos-
phorimager screen (Kodak) for 20 h. Image was captured and
analysed using ImageQuant software (Molecular Dynamics). Radio-
labelled markers (Rainbow) were from Amersham Biotech. For the in
vitro assay using cell extracts, an extract (lysate A) was prepared from
HeLa cells that had been transfected with myc-hApg5 for 48 h. Con-
trol or apoptotic lysates (lysates B) were obtained from HeLa cells left
untreated, or treated with either Sts or with TNFK and CHX as
described above by extraction into ice-cold bu¡er containing 10
mM HEPES pH 7.4, 42 mM KCl, 0.1% Triton X-100, 5 mM MgCl2,
1 mM DTT, 1 Wg/ml of pepstatin A and leupeptin and 5 Wg/ml apro-
tinin and sonication in a bath sonicator for 5 min in ice water. 16 Wg
of lysate A in 4 Wl and 32 Wg of lysate B in 8 Wl were mixed into 12 Wl
of caspase assay bu¡er containing 20 mM HEPES pH 7.4, 0.1%
CHAPS, 1 mM EDTA, 10% sucrose, 5 mM DTT and left to incubate
for 16 h at 30‡C. Western blots were prepared as described above and
probed with 9E10 or with a monoclonal antibody against poly-(ADP-
ribose) polymerase (PARP) (a kind gift from Dr Said Aufouchi (Cam-
bridge).
3. Results and discussion
In HeLa cells transfected with myc-hApg5, cells that stained
with the anti-myc antibody 9E10 were also co-incidentally
stained with the antibody raised against the TPTPTQFLC-
PKNVTD epitope in c-Jun (c-Jun(N)Ab from Santa Cruz,
SC-45) (Fig. 1A). Little staining was detected with the
c-Jun(N)Ab in untreated cells. Myc-hApg5 staining showed
a widespread punctate distribution throughout the cytoplasm
similar to the pattern for GFP-Apg5 described by Mishizuma
et al. [11]. It is likely that the anti-myc antibody recognised
hApg5 rather than other cellular proteins that are induced
during apoptosis since HeLa cells induced to undergo apo-
ptosis with Sts showed substantially elevated staining with
c-Jun(N)Ab, but there was no increase in staining with
9E10. A slight increase in cell death from 1.1T 0.9% to
7T 6% (meanT range from two independent experiments)
was found in the myc-positive transfected cells, but since
this increase was not reversed by the general caspase inhibitor
BAF, we ascribe this increase to the toxicity of the transfec-
tion rather than to apoptosis mediated by the protein.
Apoptotically induced cells that were stained with the anti-
c-Jun Ab showed both cytoplasmic and nuclear staining, as
discussed previously [7,10,12]. However, there was no di¡er-
ence in the percentages of apoptotic cells scored in the total
population of cells (22.7 T 6.9%) or in the myc-positive pop-
ulation of cells (23.2 T 4.7%) (meanT range, n=2). Addition
of BAF together with Sts inhibited apoptosis in both cell
populations, (0.68T 0.42% and 5.6T 2% in total and myc-pos-
itive populations, respectively) as described by Hammond et
al. [2]. Thus there is a strong correlation between myc-hApg5
expression and reactivity with c-Jun(N)Ab. However, there
was no signi¢cant induction of apoptosis in the over-express-
ing cells, consistent with the results of Hammond et al. [2].
Grand et al. [1] reported that p45ASP was di⁄cult to ex-
tract from cells, and that harsh conditions such as 6 M urea
or 2% SDS were required to solubilise the protein. Consistent
with this result, we also found that myc-hApg5 was di⁄cult to
extract from the HeLa cells. However, the relative distribution
of the two proteins di¡ered during apoptosis. Fig. 1B shows
that when untransfected cells were induced to undergo apo-
ptosis with staurosporine and extracted with gentle lysis bu¡er
containing 1% Triton X-100, about 60% of the total p45ASP
was found in the extract, the remainder being found in the 2%
SDS-extractable pellet. The same result was found using 6 M
urea (data not shown). However, in HeLa cells that were ¢rst
transfected with myc-hApg5 and then induced to undergo ap-
optosis with staurosporine, no soluble myc-hApg5 was de-
tected in the Triton X-100 extract, most of the remaining
protein being associated with the pellet. There was no increase
in hApg5 in the pellet during the period when hApg5 disap-
peared from the soluble fraction, suggesting that the decrease
in the amount of hApg5 in the soluble fraction was not due to
a redistribution of the protein into the pellet. Moreover, since
hApg5 was detected either with the anti-myc Ab or with anti-
c-Jun(N) antibody, which does not recognise the myc epitope
(L. Xue, unpublished data) it is unlikely that the reason for
the loss of myc-hApg5 expression in the soluble fraction was
due to a cleavage of the myc epitope (which terminates in the
peptide SEEDL) by caspases.
These data suggested that conditions that stabilise p45ASP
during apoptosis promote the degradation of hApg5 and that
soluble hApg5 is a labile protein. To examine this question
further, we took advantage of the fact that TNFK and CHX
stimulate apoptosis in HeLa cells and increase expression of
p45ASP whilst preventing protein synthesis. Myc-hApg5 was
¢rst expressed for 48 h and then apoptosis was induced with
TNFK and CHX for 8 h in the presence or absence of BAF.
As predicted from the results with staurosporine, the levels of
p45ASP were increased during the stimulus with TNFK and
CHX, but hApg5 levels detected with either anti-c-Jun(N) or
anti-myc decreased. However, the opposite occurred when
cells were treated with TNFK and CHX in the presence of
BAF: p45ASP induction was eliminated but hApg5 expres-
sion was unaltered.
Thus, hApg5 and p45ASP di¡er in a number of character-
istics: hApg5 is unstable during apoptosis whereas p45ASP
levels increase. In contrast, BAF inhibits p45ASP expression
but stabilises that of hApg5. These results cannot be explained
solely by the fact that one protein is endogenous whilst the
other is expressed o¡ a CMV-driven promoter as CMV-EGFP
expression is not reduced when HeLa cells are treated with
TNFK and CHX. Most crucially, we never observed a p45
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Fig. 1. A: hApg5 cross-reacts with the anti-c-Jun antibody (SC-45). HeLa cells transfected with myc-hapg5 cDNA were ¢xed and co-stained
with the anti-myc antibody 9E10 and the anti-c-Jun antibody (SC-45) using secondary antibodies conjugated to FITC (myc) or cy3 (c-Jun(N).
Nuclei were visualised using Hoechst 33342. Row 1: Untransfected cells. Note low levels of c-myc and ‘c-Jun’ staining. Row 2: 14 h prior to
¢xation a set of untransfected cells was treated with 2.5 WM Sts to generate a positive control for ASP. Note lack of myc-positive cells but
presence of brightly-stained ‘c-Jun’-positive cells, some of which show DNA condensation and fragmentation typical of apoptotic HeLa cells.
Row 3: HeLa cells ¢xed 48 h after transfection. Note lack of apoptotic features and presence of myc- and ‘c-Jun’-positive co-stained cells. B:
Di¡erential stability and localisation of myc-hApg5 and endogenous p45ASP. HeLa cells transfected for 48 h were treated with 2.5 WM Sts for
14 h. Cells were lysed in a mild lysis bu¡er containing 1% Triton X-100, spun and the supernatant (sup) was separated from the pellet, which
was lysed in 2% SDS lysis bu¡er. Protein samples (50 Wg per lane) were resolved on a 10% denaturing polyacrylamide gel and analysed by
Western blotting using the anti-c-Jun(N) antibody SC-45 (panels 1 and 2) or the anti-myc antibody (9E10) (panels 3 and 4). The bottom-most
panel shows amido black staining as a loading control. *, non-speci¢c band staining with 9E10. Note that Sts induces the appearance of ASP
in the soluble fraction, but causes the concomitant degradation of myc-hApg5, detected with 9E10 or the c-Jun(N) antibody. Myc-hApg5 is ap-
parently more stable than ASP in the pellet fraction. C: HeLa cells were treated with 50 ng/ml TNFK and 20 Wg/ml CHX in the absence or
presence of BAF for 8 h, after which soluble proteins were extracted and analysed by Western blotting. Note that despite the presence of su⁄-
cient CHX to prevent s 95% of protein synthesis, ASP is still induced by TNFK and this induction is inhibited by BAF. In contrast, myc-
hApg5 expression disappears during TNFK and CHX treatment but BAF prevents this disappearance. Non-speci¢c staining indicated with *
for anti-c-Jun(N) or ** for 9E10 (used as loading controls for the upper and lower panels, respectively).
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kDa protein of the size of p45ASP to be formed from myc-
hApg5 during apoptotic induction.
One remaining question is why ^ if hApg5 is not an ‘ASP’ ^
does it cross-react with the anti-c-Jun(N) antibody? Given
that Casas et al. [10] suggested that it is a newly created c-
terminal VTD motif that is recognised by the c-Jun antibody
in most ASP proteins, and that myc-hApg5 contains a VTD
motif at amino acids 47^50, we examined whether hApg5 may
be cleaved at this VTD site. Perhaps cleavage at other puta-
tive caspase cleavage sites (such as after the sequence EAD at
amino acids 131^133) might explain the disappearance of its
soluble form from apoptotic cells. To examine whether hApg5
could be cleaved by caspases, we performed two types of
assays. In one assay we incubated in vitro translated hApg5
with recombinant caspase-3 or an apoptotic extract. If cleav-
age at the VTD site were to occur, the size of hApg5 should
decrease by about 5 kDa, similar to the decrease in size pre-
dicted for an in vitro translated fragment of retinoblastoma
(Rb(378^938)) if it were cleaved after D in the DEADG(883-
6) sequence. However, no cleavage of in vitro translated
hApg5 was observed (Fig. 2A) although Rb(378^938) was
cleaved appropriately, showing that caspase-3 was active.
Moreover, this cleavage was inhibited by DEVD-CHO. The
two proteins were also submitted to cleavage by an apoptotic
extract from HeLa cells treated with Sts and again, only
Rb(378^938) was cleaved in a DEVD-CHO inhibitable man-
ner. In a second type of assay, a HeLa cell extract containing
cellular myc-hApg5 was exposed to a cytosolic extract derived
from either Sts or TNFK/CHX-stimulated apoptotic HeLa
cells. Once again, no cleavage of myc-hApg5 was observed
although PARP was cleaved appropriately in a BAF-inhibit-
able manner. Thus it is unlikely that the disappearance of
soluble hApg5 during apoptosis is due to its cleavage by cas-
pase-3 (or caspase-8, which is activated by TNFK/CHX treat-
ment in HeLa cells).
In summary, we suggest that p45ASP and hApg5 are un-
related proteins that share the property (along with several
other proteins) of interacting with c-Jun polyclonal antibodies
raised against the TPTPTQFLCPKNVTD motif. If the sug-
gestion that VTD serves as the recognition motif for the c-Jun
Fig. 2. A: In vitro translated hApg5 (lanes 4^6 and 8^10) or Rb(378^938) (lanes 1^3, 9 and 10) were incubated for 16 h with recombinant cas-
pase-3 (lanes 2, 3, 5 and 6) or with an apoptotic extract derived from HeLa cells treated with Sts for 4 h (lanes 9^12). The extracts were re-
solved by SDS^PAGE and imaged using a phosphorimager. Lane 8 (C*) signi¢es addition of a non-apoptotic HeLa cell extract. B: A lysate
from myc-hApg5-expressing HeLa cells (lanes 3^6 and 8^11) was either left untouched (duplicate lanes 3 and 8), or mixed with a cell extract
derived from untreated (C) (duplicate lanes 4 and 9), or Sts-treated (S) (lanes 5 and 6) or TNFK and CHX (Tc) treated (lanes 10 and 11)
HeLa cells and left to incubate for 16 h. BAF (10 WM) was added to the apoptotic lysates (lanes 6 and 11) before mixing with the hApg5-con-
taining extract. Extracts were analysed by Western blotting using the anti-myc antibody 9E10 (lower panels) or an anti-PARP antibody (upper
panels) to indicate presence of capsase activity. The controls in lanes 1, 2 and 7 were used to demonstrate the absence (in C) or presence of
caspase activity in S and Tc-type B lysates before their addition to the hApg5-containing lysate so they were not incubated for 16 h. Although
there was some spontaneous PARP cleavage in the Apg5-containing extract (lanes 3 and 8) incubated for 16 h, cleavage was further enhanced
by addition of apoptotic lysates (lanes 5 and 10) and this cleavage was inhibited by BAF (100 WM). The control lysate (lanes 4 and 9) had no
e¡ect.
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antibody [10] can be extended to native proteins, our data
suggest that this epitope is exposed in soluble hApg5 whilst
it is buried in the tethered form. Presumably the P1P lysine in
the LVTDK sequence prevents its cleavage by caspases as the
amino acids in position P2-4 are not unfavourable to cleavage
by a combination of caspases (such as caspase-2, -3 and -8)
[13]. Thus the identities of p45ASP and the protease(s) re-
sponsible for the disappearance of hApg5 remain to be re-
solved.
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